drugset
drugset / Trial / NCT04508179

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

NCT04508179 ↗

Phase 1 Completed 60 enrolled 7 Hills Pharma, LLC Frontage Clinical Services, Inc. · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This study will evaluate the safety, tolerability and pharmacokinetics of 7HP349, an allosteric integrin activator, in healthy male subjects

Timeline

Start
2020-10-28
Primary completion
2021-10-25
Completion
2021-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Alintegimod Small molecule — Oral

Indications

cancer